Eric van der Veer, PhD

Chief Innovation Officer at Hybridize Therapeutics

Speaker

Eric van der Veer PhD studied chemistry at the University of Amsterdam and obtained his PhD degree at the University of Western Ontario (London, Ontario, Canada), where he alongside high-impact publications, obtained several patents in the field of cellular aging. He returned to the Netherlands and started his own research group at the Leiden University Medical Center (Nephrology) specializing in RNA biology. In 2015, Eric transitioned his research focus to the development of RNA therapeutic strategies for kidney diseases, thereby focusing on BK virus in the setting of kidney and hematopoietic stem cell transplantation. In 2019, Eric founded Hybridize Therapeutics with the goal to move these RNA-based technologies to kidney patients. In 2022, Hybridize Therapeutics outlicensed this BK virus-targeting ASO to AiCuris Anti-Infectives Cures AG.